{
    "id": "46db7808-58a2-4ec9-aa54-17c2602da528",
    "indications": {
        "text": "vegzelma vascular endothelial growth factor inhibitor indicated treatment : metastatic colorectal cancer , combination intravenous fluorouracil-based chemotherapy first- second-line treatment . ( 1.1 ) metastatic colorectal cancer , combination fluoropyrimidine-irinotecan- fluoropyrimidine-oxaliplatin-based chemotherapy second-line treatment patients progressed first-line bevacizumab product-containing regimen . ( 1.1 ) limitations : vegzelma indicated adjuvant treatment colon cancer . ( 1.1 ) unresectable , locally advanced , recurrent metastatic non-squamous non-small cell lung cancer , combination carboplatin paclitaxel first-line treatment . ( 1.2 ) recurrent glioblastoma adults . ( 1.3 ) metastatic renal cell carcinoma combination interferon alfa . ( 1.4 ) persistent , recurrent , metastatic cervical cancer , combination paclitaxel cisplatin , paclitaxel topotecan . ( 1.5 ) epithelial ovarian , fallopian tube , primary peritoneal cancer : combination carboplatin paclitaxel , followed vegzelma single agent , stage iii iv disease following initial surgical resection ( 1.6 ) combination paclitaxel , pegylated liposomal doxorubicin , topotecan platinum-resistant recurrent disease received 2 prior chemotherapy regimens ( 1.6 ) combination carboplatin paclitaxel carboplatin gemcitabine , followed vegzelma single agent , platinum-sensitive recurrent disease ( 1.6 )",
        "doid_entities": [
            {
                "text": "colorectal cancer (DOID:9256)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9256"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "colon cancer (DOID:219)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_219"
            },
            {
                "text": "non-small cell lung cancer (DOID:3908)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3908"
            },
            {
                "text": "lung cancer (DOID:1324)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1324"
            },
            {
                "text": "glioblastoma (DOID:3068)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3068"
            },
            {
                "text": "renal cell carcinoma (DOID:4450)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4450"
            },
            {
                "text": "carcinoma (DOID:305)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_305"
            },
            {
                "text": "cervical cancer (DOID:4362)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4362"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "withhold least 28 days prior elective surgery . administer vegzelma 28 days following major surgery adequate wound healing . ( 2.1 ) metastatic colorectal cancer ( 2.2 ) 5 mg/kg every 2 weeks bolus-ifl 10 mg/kg every 2 weeks folfox4 5 mg/ kg every 2 weeks 7.5 mg/kg every 3 weeks fluoropyrimidine-irinotecan- fluoropyrimidine-oxaliplatin based chemotherapy progression first-line bevacizumab product containing regimen first-line non\u2212squamous non\u2212small cell lung cancer ( 2.3 ) 15 mg/kg every 3 weeks carboplatin paclitaxel recurrent glioblastoma ( 2.4 ) 10 mg/kg every 2 weeks metastatic renal cell carcinoma ( 2.5 ) 10 mg/kg every 2 weeks interferon alfa persistent , recurrent , metastatic cervical cancer ( 2.6 ) 15 mg/kg every 3 weeks paclitaxel cisplatin , paclitaxel topotecan stage iii iv epithelial ovarian , fallopian tube primary peritoneal cancer following initial surgical resection ( 2.7 ) 15 mg/kg every 3 weeks carboplatin paclitaxel 6 cycles , followed 15 mg/kg every 3 weeks single agent , total 22 cycles platinum-resistant recurrent epithelial ovarian , fallopian tube primary peritoneal cancer ( 2.7 ) 10 mg/kg every 2 weeks paclitaxel , pegylated liposomal doxorubicin , topotecan given every week 15 mg/kg every 3 weeks topotecan given every 3 weeks platinum-sensitive recurrent epithelial ovarian , fallopian tube , primary peritoneal cancer ( 2.7 ) 15 mg/kg every 3 weeks carboplatin paclitaxel 6-8 cycles , followed 15 mg/kg every 3 weeks single agent 15 mg/kg every 3 weeks carboplatin gemcitabine 6-10 cycles , followed 15 mg/kg every 3 weeks single agent administer intravenous infusion dilution . full prescribing informatio preparation instructions modifications . ( 2.8 2.9 )",
        "doid_entities": [
            {
                "text": "colorectal cancer (DOID:9256)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9256"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "non\u2212small cell lung cancer (DOID:3908)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3908"
            },
            {
                "text": "lung cancer (DOID:1324)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1324"
            },
            {
                "text": "glioblastoma (DOID:3068)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3068"
            },
            {
                "text": "renal cell carcinoma (DOID:4450)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4450"
            },
            {
                "text": "carcinoma (DOID:305)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_305"
            },
            {
                "text": "cervical cancer (DOID:4362)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4362"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "vegzelma ( bevacizumab-adcd ) injection clear opalescent , colorless pale brown , sterile solution intravenous infusion supplied single-dose vial pakcaged within cartons following strengths packaging configurations : 100 mg/4 ml ( 25 mg/ml ) : carton one vial ( ndc 72606-011-01 ) ; carton 10 vials ( ndc 72606-011-10 ) . 400 mg/16 ml ( 25 mg/ml ) : carton one vial ( ndc 72606-012-01 ) ; carton 10 vials ( ndc 72606-012-10 ) .",
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "BEVACIZUMAB",
            "code": "2S9ZZM9Q9V",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00112"
        },
        {
            "name": "TREHALOSE DIHYDRATE",
            "code": "7YIN7J07X4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_232797"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, ANHYDROUS",
            "code": "22ADO53M6F",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53424"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE",
            "code": "593YOG76RN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "organization": "CELLTRION USA, Inc.",
    "name": "Vegzelma",
    "effectiveTime": "20250508",
    "indications_original": "VEGZELMA is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : VEGZELMA is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by VEGZELMA as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by VEGZELMA as a single agent, for platinum-sensitive recurrent disease ( 1.6 )",
    "contraindications_original": "Withhold for at least 28 days prior to elective surgery. Do not administer VEGZELMA for 28 days following major surgery and until adequate wound healing. ( 2.1 ) Metastatic colorectal cancer ( 2.2 ) 5 mg/kg every 2 weeks with bolus-IFL 10 mg/kg every 2 weeks with FOLFOX4 5 mg/ kg every 2 weeks or 7.5 mg/kg every 3 weeks with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin based chemotherapy after progression on a first-line bevacizumab product containing regimen First-line non\u2212squamous non\u2212small cell lung cancer ( 2.3 ) 15 mg/kg every 3 weeks with carboplatin and paclitaxel Recurrent glioblastoma ( 2.4 ) 10 mg/kg every 2 weeks Metastatic renal cell carcinoma ( 2.5 ) 10 mg/kg every 2 weeks with interferon alfa Persistent, recurrent, or metastatic cervical cancer ( 2.6 ) 15 mg/kg every 3 weeks with paclitaxel and cisplatin, or paclitaxel and topotecan Stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer following initial surgical resection ( 2.7 ) 15 mg/kg every 3 weeks with carboplatin and paclitaxel for up to 6 cycles, followed by 15 mg/kg every 3 weeks as a single agent, for a total of up to 22 cycles Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer ( 2.7 ) 10 mg/kg every 2 weeks with paclitaxel, pegylated liposomal doxorubicin, or topotecan given every week 15 mg/kg every 3 weeks with topotecan given every 3 weeks Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer ( 2.7 ) 15 mg/kg every 3 weeks with carboplatin and paclitaxel for 6-8 cycles, followed by 15 mg/kg every 3 weeks as a single agent 15 mg/kg every 3 weeks with carboplatin and gemcitabine for 6-10 cycles, followed by 15 mg/kg every 3 weeks as a single agent Administer as an intravenous infusion after dilution. See full Prescribing Informatio for preparation and administration instructions and dosage modifications for adverse reactions. ( 2.8 and 2.9 )",
    "warningsAndPrecautions_original": "VEGZELMA (bevacizumab-adcd) injection is a clear to opalescent, colorless to pale brown, sterile solution for intravenous infusion supplied in a single-dose vial pakcaged within cartons in the following strengths and packaging configurations:\n                  \n                  \n                     100 mg/4 mL (25 mg/mL): carton of one vial (NDC 72606-011-01); carton of 10 vials (NDC 72606-011-10).\n                     400 mg/16 mL (25 mg/mL): carton of one vial (NDC 72606-012-01); carton of 10 vials (NDC 72606-012-10).",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Vegzelma",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00112"
        }
    ]
}